News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,486 Results
Type
Article (13590)
Company Profile (110)
Press Release (247786)
Section
Business (87950)
Career Advice (462)
Deals (15326)
Drug Delivery (64)
Drug Development (36532)
Employer Resources (49)
FDA (6259)
Job Trends (6185)
News (150032)
Policy (14007)
Tag
Academia (435)
Alliances (23105)
Alzheimer's disease (354)
Approvals (6256)
Artificial intelligence (63)
Bankruptcy (143)
Best Places to Work (4335)
Biotechnology (44)
Breast cancer (48)
Cancer (335)
Career advice (405)
Cell therapy (47)
Clinical research (30436)
Collaboration (166)
Compensation (66)
COVID-19 (747)
C-suite (55)
Data (360)
Diabetes (54)
Diagnostics (1238)
Drug pricing (57)
Earnings (31570)
Employer resources (43)
Events (36808)
Executive appointments (178)
FDA (6448)
Funding (109)
Gene therapy (59)
GLP-1 (295)
Government (1267)
Healthcare (3526)
Infectious disease (765)
Inflammatory bowel disease (47)
Interviews (58)
IPO (5823)
Job creations (2050)
Job search strategy (372)
Layoffs (167)
Legal (3411)
Lung cancer (48)
Manufacturing (100)
Medical device (1262)
Medtech (1264)
Mergers & acquisitions (9549)
Metabolic disorders (169)
Neuroscience (453)
NextGen Class of 2024 (1580)
Non-profit (590)
Northern California (449)
Obesity (101)
Opinion (109)
Patents (56)
People (28479)
Pharmaceutical (64)
Phase I (7912)
Phase II (12866)
Phase III (11569)
Pipeline (187)
Policy (45)
Postmarket research (1399)
Preclinical (3169)
Radiopharmaceuticals (116)
Rare diseases (92)
Real estate (2629)
Regulatory (9836)
Research institute (563)
Resumes & cover letters (55)
Southern California (445)
Startups (1625)
United States (4424)
Vaccines (112)
Weight loss (78)
Date
Today (37)
Last 7 days (132)
Last 30 days (1080)
Last 365 days (12631)
2024 (11845)
2023 (14245)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (43)
Asia (19819)
Australia (2560)
California (1040)
Canada (624)
China (122)
Colorado (43)
Connecticut (44)
Europe (38810)
Florida (157)
Illinois (117)
Indiana (87)
Japan (43)
Kansas (51)
Maryland (162)
Massachusetts (913)
Minnesota (60)
New Jersey (443)
New York (287)
North Carolina (281)
Northern California (449)
Pennsylvania (293)
South America (498)
Southern California (445)
Texas (148)
Virginia (41)
Washington State (71)
261,486 Results for "scilex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
October 28, 2024
·
14 min read
Biotech Bay
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides information to its stockholders regarding short selling of Scilex common stocks traded on the Nasdaq Capital Market.
May 13, 2024
·
12 min read
Press Releases
Scilex Holding Company Announces Receipt of Notice from Nasdaq
November 22, 2024
·
6 min read
Press Releases
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential
October 16, 2024
·
10 min read
Press Releases
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
October 29, 2024
·
13 min read
Policy
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).
February 27, 2024
·
5 min read
Business
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
Scilex Holding Company announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC.
June 20, 2024
·
7 min read
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
Scilex Holding Company provided certain preliminary unaudited financial results for the month ended June 30, 2024 and quarter ended June 30, 2024.
July 1, 2024
·
8 min read
Drug Development
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”) today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research on the nature, mechanisms and treatment of pain.
June 14, 2024
·
9 min read
Biotech Bay
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that many national pharmacy chains and independent pharmacy stores have begun stocking GLOPERBA®.
June 11, 2024
·
6 min read
1 of 26,149
Next
